Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.18
AGN's Cash-to-Debt is ranked lower than
87% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. AGN: 0.18 )
Ranked among companies with meaningful Cash-to-Debt only.
AGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.59 Max: 43.62
Current: 0.18
0.01
43.62
Equity-to-Asset 0.60
AGN's Equity-to-Asset is ranked lower than
55% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. AGN: 0.60 )
Ranked among companies with meaningful Equity-to-Asset only.
AGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.63 Max: 0.93
Current: 0.6
0.25
0.93
Debt-to-Equity 0.43
AGN's Debt-to-Equity is ranked lower than
58% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. AGN: 0.43 )
Ranked among companies with meaningful Debt-to-Equity only.
AGN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.3 Max: 1.8
Current: 0.43
0.01
1.8
Debt-to-EBITDA -10.50
AGN's Debt-to-EBITDA is ranked lower than
96% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. AGN: -10.50 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AGN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.5  Med: 4.46 Max: 64.18
Current: -10.5
-10.5
64.18
Piotroski F-Score: 6
Altman Z-Score: 0.69
Beneish M-Score: -2.59
WACC vs ROIC
5.38%
-4.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -43.48
AGN's Operating Margin % is ranked lower than
80% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. AGN: -43.48 )
Ranked among companies with meaningful Operating Margin % only.
AGN' s Operating Margin % Range Over the Past 10 Years
Min: -54.9  Med: 6.95 Max: 14.13
Current: -43.48
-54.9
14.13
Net Margin % -46.82
AGN's Net Margin % is ranked higher than
99% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. AGN: -46.82 )
Ranked among companies with meaningful Net Margin % only.
AGN' s Net Margin % Range Over the Past 10 Years
Min: -46.82  Med: 5.67 Max: 102.76
Current: -46.82
-46.82
102.76
ROE % -9.71
AGN's ROE % is ranked higher than
74% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. AGN: -9.71 )
Ranked among companies with meaningful ROE % only.
AGN' s ROE % Range Over the Past 10 Years
Min: -11.23  Med: 7.32 Max: 19.24
Current: -9.71
-11.23
19.24
ROA % -5.63
AGN's ROA % is ranked higher than
75% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. AGN: -5.63 )
Ranked among companies with meaningful ROA % only.
AGN' s ROA % Range Over the Past 10 Years
Min: -5.63  Med: 4.03 Max: 11.32
Current: -5.63
-5.63
11.32
ROC (Joel Greenblatt) % -593.79
AGN's ROC (Joel Greenblatt) % is ranked lower than
86% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. AGN: -593.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -593.79  Med: 20.42 Max: 38.44
Current: -593.79
-593.79
38.44
3-Year Revenue Growth Rate 27.40
AGN's 3-Year Revenue Growth Rate is ranked higher than
90% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. AGN: 27.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.3  Med: 17.5 Max: 40.4
Current: 27.4
-16.3
40.4
3-Year EBITDA Growth Rate 41.70
AGN's 3-Year EBITDA Growth Rate is ranked higher than
87% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. AGN: 41.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.7  Med: 13.1 Max: 67.4
Current: 41.7
-47.7
67.4
3-Year EPS without NRI Growth Rate -1.20
AGN's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. AGN: -1.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.1  Med: 5.4 Max: 94.3
Current: -1.2
-27.1
94.3
GuruFocus has detected 1 Warning Sign with Allergan PLC AGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AGN's 30-Y Financials

Financials (Next Earnings Date: 2018-02-22)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

AGN Guru Trades in Q4 2016

First Eagle Investment 26,600 sh (New)
Joel Greenblatt 116,791 sh (New)
NWQ Managers 280,596 sh (New)
Steven Cohen 84,101 sh (New)
First Pacific Advisors 16,500 sh (New)
Tom Gayner 14,000 sh (+600.00%)
David Tepper 4,261,406 sh (+249.78%)
Seth Klarman 3,432,603 sh (+71.46%)
Jerome Dodson 170,000 sh (+62.68%)
Scott Black 8,147 sh (+27.20%)
Pioneer Investments 1,229,649 sh (+25.19%)
Mario Gabelli 68,848 sh (+22.97%)
John Griffin 1,539,500 sh (+22.26%)
Jeff Auxier 7,840 sh (+16.15%)
Paul Tudor Jones 31,400 sh (+14.48%)
Private Capital 149,819 sh (+11.25%)
Vanguard Health Care Fund 12,649,139 sh (+6.14%)
Wallace Weitz 637,733 sh (+4.55%)
Diamond Hill Capital 53,883 sh (+3.27%)
Ken Fisher 4,048 sh (+0.60%)
Robert Bruce 25,000 sh (unchged)
Carl Icahn 425,438 sh (unchged)
John Paulson 214,700 sh (unchged)
Paul Singer 1,000,000 sh (unchged)
Paul Singer 2,735,000 sh (unchged)
David Carlson 450,000 sh (unchged)
Bernard Horn 17,389 sh (unchged)
Ruane Cunniff Sold Out
Daniel Loeb Sold Out
John Burbank Sold Out
Alan Fournier Sold Out
George Soros 77,135 sh (-4.46%)
Manning & Napier Advisors, Inc 9,880 sh (-5.99%)
John Paulson 3,554,734 sh (-8.65%)
Ron Baron 14,572 sh (-14.83%)
Leon Cooperman 363,788 sh (-32.77%)
Eaton Vance Worldwide Health Sciences Fund 321,548 sh (-8.36%)
» More
Q1 2017

AGN Guru Trades in Q1 2017

Andreas Halvorsen 250,577 sh (New)
Jim Simons 520,069 sh (New)
Frank Sands 5,553 sh (New)
Robert Bruce 50,000 sh (+100.00%)
Tom Gayner 27,000 sh (+92.86%)
Steven Cohen 130,000 sh (+54.58%)
Ken Fisher 5,099 sh (+25.96%)
John Griffin 1,909,900 sh (+24.06%)
Manning & Napier Advisors, Inc 11,980 sh (+21.26%)
David Carlson 470,000 sh (+4.44%)
Jerome Dodson 177,000 sh (+4.12%)
Mario Gabelli 70,958 sh (+3.06%)
Pioneer Investments 1,258,536 sh (+2.35%)
Jeff Auxier 7,960 sh (+1.53%)
Scott Black 8,239 sh (+1.13%)
Private Capital 150,587 sh (+0.51%)
Bernard Horn 17,389 sh (unchged)
George Soros Sold Out
Ron Baron Sold Out
First Eagle Investment Sold Out
Carl Icahn Sold Out
Paul Singer Sold Out
Signature Select Canadian Fund Sold Out
Vanguard Health Care Fund 11,681,634 sh (-7.65%)
John Paulson 2,941,834 sh (-17.24%)
Leon Cooperman 295,188 sh (-18.86%)
Wallace Weitz 512,403 sh (-19.65%)
Seth Klarman 2,432,603 sh (-29.13%)
David Tepper 2,937,121 sh (-31.08%)
First Pacific Advisors 10,400 sh (-36.97%)
NWQ Managers 172,201 sh (-38.63%)
Paul Tudor Jones 4,591 sh (-85.38%)
Joel Greenblatt 3,796 sh (-96.75%)
Diamond Hill Capital 1,290 sh (-97.61%)
Eaton Vance Worldwide Health Sciences Fund 281,471 sh (-12.46%)
» More
Q2 2017

AGN Guru Trades in Q2 2017

Manning & Napier Advisors, Inc 18,035 sh (+50.54%)
Diamond Hill Capital 1,687 sh (+30.78%)
Bernard Horn 21,989 sh (+26.45%)
Tom Gayner 33,000 sh (+22.22%)
Pioneer Investments 1,340,783 sh (+6.54%)
Ken Fisher 5,314 sh (+4.22%)
Jerome Dodson 183,000 sh (+3.39%)
Jeff Auxier 8,010 sh (+0.63%)
Mario Gabelli 71,323 sh (+0.51%)
David Carlson 470,000 sh (unchged)
Robert Bruce 50,000 sh (unchged)
Seth Klarman 2,432,603 sh (unchged)
Leon Cooperman 295,188 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 281,471 sh (unchged)
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Vanguard Health Care Fund 11,426,334 sh (-2.19%)
Frank Sands 5,428 sh (-2.25%)
Private Capital 146,853 sh (-2.48%)
NWQ Managers 164,265 sh (-4.61%)
Scott Black 7,814 sh (-5.16%)
Wallace Weitz 481,895 sh (-5.95%)
First Pacific Advisors 9,700 sh (-6.73%)
John Paulson 2,703,570 sh (-8.10%)
David Tepper 2,509,619 sh (-14.56%)
John Griffin 1,438,000 sh (-24.71%)
Jim Simons 234,169 sh (-54.97%)
» More
Q3 2017

AGN Guru Trades in Q3 2017

Paul Tudor Jones 7,925 sh (New)
George Soros 1,100 sh (New)
Steven Cohen 449,776 sh (New)
Caxton Associates 2,100 sh (New)
Ken Fisher 7,015 sh (+32.01%)
Bernard Horn 27,289 sh (+24.10%)
Seth Klarman 2,964,203 sh (+21.85%)
Wallace Weitz 523,810 sh (+8.70%)
Jeff Auxier 8,495 sh (+6.05%)
Frank Sands 5,618 sh (+3.50%)
David Carlson 480,000 sh (+2.13%)
Pioneer Investments 1,355,733 sh (+1.12%)
Scott Black 7,884 sh (+0.90%)
Tom Gayner 33,000 sh (unchged)
Robert Bruce 50,000 sh (unchged)
Leon Cooperman Sold Out
Vanguard Health Care Fund 11,337,619 sh (-0.78%)
Mario Gabelli 70,023 sh (-1.82%)
First Pacific Advisors 9,500 sh (-2.06%)
Private Capital 139,929 sh (-4.71%)
Manning & Napier Advisors, Inc 16,960 sh (-5.96%)
Diamond Hill Capital 1,540 sh (-8.71%)
John Griffin 1,283,680 sh (-10.73%)
NWQ Managers 136,976 sh (-16.61%)
John Paulson 2,180,292 sh (-19.36%)
David Tepper 1,888,188 sh (-24.76%)
Jerome Dodson 115,075 sh (-37.12%)
Jim Simons 63,169 sh (-73.02%)
Eaton Vance Worldwide Health Sciences Fund 257,544 sh (-8.50%)
» More
» Details

Insider Trades

Latest Guru Trades with AGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-09-30 Reduce -0.78%0.05%$202.66 - $256.15 $ 172.22-26%11,337,619
Seth Klarman 2017-09-30 Add 21.85%1.36%$202.66 - $256.15 $ 172.22-26%2,964,203
John Paulson 2017-09-30 Reduce -19.36%1.73%$202.66 - $256.15 $ 172.22-26%2,180,292
David Tepper 2017-09-30 Reduce -24.76%2.24%$202.66 - $256.15 $ 172.22-26%1,888,188
Wallace Weitz 2017-09-30 Add 8.70%0.36%$202.66 - $256.15 $ 172.22-26%523,810
Private Capital 2017-09-30 Reduce -4.71%0.27%$202.66 - $256.15 $ 172.22-26%139,929
NWQ Managers 2017-09-30 Reduce -16.61%0.09%$202.66 - $256.15 $ 172.22-26%136,976
Mario Gabelli 2017-09-30 Reduce -1.82%$202.66 - $256.15 $ 172.22-26%70,023
Ken Fisher 2017-09-30 Add 32.01%$202.66 - $256.15 $ 172.22-26%7,015
George Soros 2017-09-30 New Buy0.01%$202.66 - $256.15 $ 172.22-26%1,100
Leon Cooperman 2017-09-30 Sold Out 2.99%$202.66 - $256.15 $ 172.22-26%0
Vanguard Health Care Fund 2017-06-30 Reduce -2.19%0.14%$218.73 - $248.91 $ 172.22-27%11,426,334
John Paulson 2017-06-30 Reduce -8.10%0.76%$218.73 - $248.91 $ 172.22-27%2,703,570
David Tepper 2017-06-30 Reduce -14.56%1.68%$218.73 - $248.91 $ 172.22-27%2,509,619
Wallace Weitz 2017-06-30 Reduce -5.95%0.31%$218.73 - $248.91 $ 172.22-27%481,895
NWQ Managers 2017-06-30 Reduce -4.61%0.03%$218.73 - $248.91 $ 172.22-27%164,265
Private Capital 2017-06-30 Reduce -2.48%0.14%$218.73 - $248.91 $ 172.22-27%146,853
Mario Gabelli 2017-06-30 Add 0.51%$218.73 - $248.91 $ 172.22-27%71,323
Tom Gayner 2017-06-30 Add 22.22%0.03%$218.73 - $248.91 $ 172.22-27%33,000
Ken Fisher 2017-06-30 Add 4.22%$218.73 - $248.91 $ 172.22-27%5,314
Joel Greenblatt 2017-06-30 Sold Out 0.01%$218.73 - $248.91 $ 172.22-27%0
Vanguard Health Care Fund 2017-03-31 Reduce -7.65%0.49%$210.8 - $249.32 $ 172.22-26%11,681,634
John Paulson 2017-03-31 Reduce -17.24%1.64%$210.8 - $249.32 $ 172.22-26%2,941,834
David Tepper 2017-03-31 Reduce -31.08%4.93%$210.8 - $249.32 $ 172.22-26%2,937,121
Seth Klarman 2017-03-31 Reduce -29.13%2.76%$210.8 - $249.32 $ 172.22-26%2,432,603
Wallace Weitz 2017-03-31 Reduce -19.65%1.07%$210.8 - $249.32 $ 172.22-26%512,403
Leon Cooperman 2017-03-31 Reduce -18.86%0.64%$210.8 - $249.32 $ 172.22-26%295,188
NWQ Managers 2017-03-31 Reduce -38.63%0.31%$210.8 - $249.32 $ 172.22-26%172,201
Private Capital 2017-03-31 Add 0.51%0.03%$210.8 - $249.32 $ 172.22-26%150,587
Mario Gabelli 2017-03-31 Add 3.06%$210.8 - $249.32 $ 172.22-26%70,958
Robert Bruce 2017-03-31 Add 100.00%1.6%$210.8 - $249.32 $ 172.22-26%50,000
Tom Gayner 2017-03-31 Add 92.86%0.07%$210.8 - $249.32 $ 172.22-26%27,000
Ken Fisher 2017-03-31 Add 25.96%$210.8 - $249.32 $ 172.22-26%5,099
Joel Greenblatt 2017-03-31 Reduce -96.75%0.31%$210.8 - $249.32 $ 172.22-26%3,796
Carl Icahn 2017-03-31 Sold Out 0.4%$210.01 - $249.32 $ 172.22-26%0
First Eagle Investment 2017-03-31 Sold Out 0.01%$210.8 - $249.32 $ 172.22-26%0
George Soros 2017-03-31 Sold Out 0.53%$210.8 - $249.32 $ 172.22-26%0
Ron Baron 2017-03-31 Sold Out 0.02%$210.8 - $249.32 $ 172.22-26%0
Vanguard Health Care Fund 2016-12-31 Add 6.14%0.37%$188.47 - $242.65 $ 172.22-17%12,649,139
David Tepper 2016-12-31 Add 249.78%11.33%$188.47 - $242.65 $ 172.22-17%4,261,406
John Paulson 2016-12-31 Reduce -8.65%0.85%$188.47 - $242.65 $ 172.22-17%3,554,734
Seth Klarman 2016-12-31 Add 71.46%3.96%$188.47 - $242.65 $ 172.22-17%3,432,603
Wallace Weitz 2016-12-31 Add 4.55%0.24%$188.47 - $242.65 $ 172.22-17%637,733
Leon Cooperman 2016-12-31 Reduce -32.77%1.26%$188.47 - $242.65 $ 172.22-17%363,788
NWQ Managers 2016-12-31 New Buy0.8%$188.47 - $242.65 $ 172.22-17%280,596
Private Capital 2016-12-31 Add 11.25%0.49%$188.47 - $242.65 $ 172.22-17%149,819
Joel Greenblatt 2016-12-31 New Buy0.32%$188.47 - $242.65 $ 172.22-17%116,791
George Soros 2016-12-31 Reduce -4.46%0.03%$188.47 - $242.65 $ 172.22-17%77,135
Mario Gabelli 2016-12-31 Add 22.97%0.02%$188.47 - $242.65 $ 172.22-17%68,848
First Eagle Investment 2016-12-31 New Buy0.01%$188.47 - $242.65 $ 172.22-17%26,600
Ron Baron 2016-12-31 Reduce -14.83%$188.47 - $242.65 $ 172.22-17%14,572
Tom Gayner 2016-12-31 Add 600.00%0.06%$188.47 - $242.65 $ 172.22-17%14,000
Ken Fisher 2016-12-31 Add 0.60%$188.47 - $242.65 $ 172.22-17%4,048
Ruane Cunniff 2016-12-31 Sold Out 0.01%$188.47 - $242.65 $ 172.22-17%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNpA605.854.545 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:XTER:MRK, TSE:4502, NYSE:ZTS, SHSE:600276, NSE:SUNPHARMA, NAS:MYL, TSE:4507, SHSE:600518, TSE:4523, SZSE:000538, NYSE:TEVA, SHSE:600196, NYSE:PRGO, TSE:4508, OCSE:LUN, JSE:APN, XPAR:IPN, XSWX:VIFN, HKSE:03320, SZSE:000963 » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Headquarter Location:Ireland
Allergan PLC is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and OTC pharmaceutical products.

Allergan is one of the largest specialty pharmaceutical manufacturers. It specializes in aesthetics, ophthalmology, women's health, gastrointestinal, and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva.

Guru Investment Theses on Allergan PLC

Jerome Dodson Comments on Allergan - Oct 25, 2017

Allergan (NYSE:AGN), a pharmaceutical company best known for developing Botox, fell 15.7% from $243.09 to $204.95, reducing the Fund’s return by 55 basis points. The stock dropped after the company announced a deal with the Saint Regis Mohawk Tribe, whereby Allergan transferred patents on its $1.5 billion dry eye drug, Restasis, to the tribe in exchange for an upfront payment and annual royalties. While this deal has the potential to delay generic competition due to the tribe’s sovereign immunity, it has also attracted political scrutiny, which weighed on the stock’s multiple. We trimmed our position to reflect our disappointment with this unusual deal. However, we continue to own the stock because we like the company’s aesthetics franchise and think the stock is significantly undervalued, trading at just 12 times expected 2018 earnings.



From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund third quarter 2017 commentary.

Check out Jerome Dodson latest stock trades

Keeley Funds Comments on Allergan - Oct 24, 2017

Pharmaceutical maker Allergan (NYSE:AGN) (-15% Q3) adversely impacted quarterly results as investors began to question the company’s near-term estimates, reversing gains from earlier this year. We continue to believe the company is well positioned to deliver double-digit returns over the midterm and added incrementally to our holdings.

From Wallace Weitz (Trades, Portfolio)'s Partners III Fund third-quarter 2017 shareholder commentary.

Check out Keeley Asset Management Corp latest stock trades

Weitz Value Fund Comments on Allergan - Apr 27, 2017

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter pharmaceutical products. Allergan shares finished 2016 on a higher note, following an otherwise challenging year. While revenues and earnings were shy of expectations and drug price regulation dominated headlines throughout much of the past year, the health of Allergan’s core underlying growth drivers gave us confidence to continue buying shares at increasingly attractive discounts during the fourth calendar quarter. Encouragingly, recent operating results have come in ahead of internal forecasts, and the company’s initial outlook for 2017 exceeded our expectations. Growth across Allergan’s therapeutic segment looks healthy, with the global aesthetics franchise demonstrating notable strength. Headwinds from legislative and regulatory developments continue to bear monitoring,



From Weitz Value Fund first quarter 2017 commentary.



Check out Wallace Weitz latest stock trades

Jerome Dodson Comments on Allergan - Apr 26, 2017

Allergan (NYSE:AGN), a pharmaceutical company best known for developing Botox, increased the Fund’s return by 61 basis points, as the stock jumped 13.8% from $210.01 to $238.92. The shares rose after the company reported better-than-expected earnings and provided an optimistic outlook for 2017. Allergan’s strong cash-pay businesses and recently launched products—such as Vraylar, a drug used to treat schizophrenia—continue to drive growth. During the quarter, Allergan extended its dominance in the aesthetics market by acquiring Zeltiq for $2.5 billion. Zeltiq’s CoolSculpting system is the #1 non-invasive fat reduction procedure in the U.S.

Jerome Dodson (Trades, Portfolio)'s first quarter 2017 Parnassus Funds commentary.

Check out Jerome Dodson latest stock trades

Weitz Funds Comments on Allergan - Jan 26, 2017

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter pharmaceutical products. Following a brief post-election rally, the majority of the biopharmaceutical sector retreated to prior price levels as capital continued to flow out of healthcare and into industries seen as potential beneficiaries of policy shifts under the new administration. After downwardly revising future growth expectations in August and again in early November, Allergan has become a “show me” story. Patent challenges for Restasis (dry eye treatment) and Namenda XR (alzheimer’s drug) may continue to weigh on the stock in the near term, though each contributes only a small percentage of our estimate of the company’s overall intrinsic value. Over the next 3-5 years, we believe the company will have healthy mid-single digit (or better) operating profit growth. 80% of the company’s recently announced $10 billion accelerated share repurchase program is complete at an average price below $200 per share. We believe this will prove to be a prudent use of excess cash in the long run. Future capital deployment and late-stage pipeline success remain potential positives over the next 12 -24 months. We continue to believe Allergan shares present compelling value at current prices.



From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Allergan - Nov 11, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. One week after closing the sale of Actavis generics to Teva Pharmaceuticals, Allergan reported mildly disappointing top-line results for the quarter. Importantly, however, Allergan’s “core” products continue to grow nicely, with five of the company’s seven core therapeutic categories growing by double digits (in constant currency) versus the prior year. Our base case valuation of $350-360 per share does not depend on Allergan hitting CEO Brent Saunders’ goal of double- digit organic growth. However, strong, high single-digit organic sales growth appears achievable, as the company’s recently launched products continue to scale. One near-term positive of a lower share price is that Allergan’s $5 billion in share repurchases between now and year end will go further, and deployment of a portion of the company’s nearly $28 billion in cash remains a possible catalyst for the stock. The re-emergence of drug pricing as a political issue is not surprising to us as we enter the home stretch of the presidential election. We believe Secretary Clinton’s plan to control and eventually lower prescription drugs costs could negatively impact Allergan’s long-term earnings trajectory (perhaps by $2-3 per share on a base of $18), should she win the election, but with the stock at $240, we believe the risk of permanent loss is low. In short, Allergan’s risk/reward ratio (upside to base case vs. downside to low case) continues to be skewed in favor of the long-term owner.





  • From Weitz Balanced Fund third quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

Daniel Loeb Comments on Akarna Therapeutics - Nov 02, 2016

Akarna Therapeutics TPV was a founding investor in Akarna in Q1 2015. Akarna focuses on the treatment of Nonalcoholic Steatohepatitis (NASH), also known as fatty liver disease. Akarna was attractive for several reasons:



  • Large market opportunity: Epidemiologic studies suggest that NASH affects 2 – 5% of Americans and is believed to be correlated with increasing rates of obesity, diabetes, and high cholesterol. If left untreated, NASH can lead to liver fibrosis, cirrhosis, and, ultimately, end-stage liver disease. Unfortunately, there are no currently approved treatments for NASH.

  • Derisked mechanism of action: Clinical trials with bile acids have validated farnesoid X receptor agonists as a viable therapeutic agent based on clinical and histological biomarkers of the disease. These trials have also demonstrated a clear need for treatments with still improved efficacy and better side effect profiles.

  • Active area of business development: Over the past few years, the sector has seen burgeoning interest in NASH assets with partnerships or acquisitions (e.g., Gilead / Nimbus, Merck / NGM) occurring at attractive valuations.

The team at Akarna identified a potentially best-in-class lead candidate with an attractive pre-clinical profile in in vitro and animal studies. Akarna also secured a broad intellectual property portfolio around the lead compound family.



In August 2016, just 18 months after Akarna was founded, Allergan acquired the company for an upfront payment of $50 million and undisclosed potential clinical, regulatory, and commercial milestones. For Third Point Ventures, our share of the upfront payment reflects a total return of 3.1x our initial investment. If Allergan (NYSE:AGN) successfully develops and commercializes the Akarna drug, the total return on our investment could be meaningfully larger.



From Third Point's third-quarter 2016 commentary.



Check out Daniel Loeb latest stock trades

Jerome Dodson Comments on Allergan - Jul 26, 2016

Allergan (NYSE:AGN), an innovative pharmaceutical company best known for developing Botox, reduced the return by 41 basis points as the stock dropped 13.8% from $268.03 to $231.09. The shares sank after Pfizer terminated its plans to acquire Allergan for $160 billion. Pfizer walked away from the deal because of new rules from the U.S. Treasury that prevent tax-lowering corporate inversions. We used the stock’s weakness to increase our position, since Allergan has an attractive collection of durable brands. We also like the fact that the company is in the process of selling its generic drug unit to Teva for $40 billion, which will enable Allergan to repurchase stock, pay down debt and acquire innovative drug companies.


From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund second quarter 2016 commentary.

Check out Jerome Dodson latest stock trades

Weitz Funds Comments on Allergan - Jul 20, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. The dissolution of Allergan’s merger with Pfizer in April, delays in gaining Federal Trade Commission approval for the sale of its global generics business to TEVA and broader industry concern around prescription drug prices combined to push Allergan’s stock down by 26% during the first half of the calendar year. As we wrote in January, we like the stand-alone Allergan business without the generics business and believe the $ 40 billion sale to TEVA should soon close. There are a number of signs that growth in Allergan’s aesthetics franchise is accelerating, and the company’s key product launches – VIBERZI, VRAYLAR and KYBELLA – appear to be off to healthy starts. The combination of healthy organic growth, debt reduction and meaningful share repurchases should drive per share value creation over our investment horizon. We substantially increased the Fund’s Allergan position during the second quarter at attractive discounts to our business value estimate.



From Weitz Value Fund's Value second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Ruane Cunniff Comments on Allergan - Jul 13, 2016

We exited two smaller positions during the quarter. While Allergan (NYSE:AGN) has a stronger collection of assets and far better outlook than Valeant, we suspect many drug makers will face increasing pressure from health care payers who need to reduce the relentless double-digit inflation rate for branded pharmaceuticals.

From Ruane Cunniff (Trades, Portfolio)'s Sequoia Fund second quarter 2016 shareholder letter.

Check out Ruane Cunniff latest stock trades

Baron Funds Comments on Allergan plc - May 06, 2016

Our conviction to buy Allergan plc (NYSE:AGN) in the first quarter relied on differentiation of Allergan from its specialty pharmaceutical peers (Valeant, Endo, Mallinckrodt) given the quality of its asset mix (Botox, glaucoma drugs, breast implants, aesthetics, etc.) and its non-reliance on distasteful price increases for growth. Admittedly, we were aware of the potential upside to the Pfizer deal and were disappointed with the Treasury’s actions to stem tax inversions. Regardless, we were comfortable with Allergan as a stand-alone company, given the above base business married to the pending closure of the sale of Allergan’s generics portfolio to Teva for approximately $40 billion. This deal (pending over the next quarters) will help drive Allergan’s M&A efforts towards obtaining a more biotech like growth profile, which should both drive increases in top/bottom-line growth and expand the multiple at which investors are willing to value Allergan’s business. However, while our initial thesis remains intact, the entire specialty pharmaceutical space has re-rated given the above-mentioned bad actors. This has pressured the entire space, and we decided to exit specialty pharmaceuticals and focus on the more innovative biotech space going forward.





From Baron Opportunity Fund first quarter 2016 commentary.







Check out Ron Baron latest stock trades

Weitz Funds Comments on Allergan - Apr 25, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focused on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter pharmaceutical products. A combination of factors contributed to the decline in Allergan’s stock during the quarter, including continued discussions of potential drug price regulation, regulatory delays in closing the company’s sale of its generic drug operations to TEVA and uncertainty around the viability of the proposed merger with Pfizer (which, subsequent to quarter end, has officially been called off). We believe the risk of the TEVA transaction falling through is low, and the company’s collection of durable growth assets, management acumen and balance sheet optionality create multiple paths for durable shareholder value creation in the years ahead. We added to our position during the quarter.



From Weitz Funds' Research Fund commentary 1st quarter.



Check out Wallace Weitz latest stock trades

Bernard Horn Comments on Allergan PLC - Mar 21, 2016

In healthcare, pharmaceutical maker Allergan PLC (NYSE:AGN) was expected to achieve 80% of an estimated $1.8 billion in synergies stemming from recent acquisitions by the end of the first quarter of 2016. With valuable drugs like Botox and a rich R&D pipeline, Allergan was approached by Pfizer. Pfizer held preliminary and friendly discussions to acquire Allergan, which will offer Pfizer a low tax domicile in Dublin.

From Bernard Horn (Trades, Portfolio)'s Global Value Fund annual letter 2015.



Check out Bernard Horn latest stock trades

GAMCO Global Growth Fund Comments on Allergan Plc - Feb 22, 2016

Allergan plc (NYSE:AGN) (3.4% of net assets as of December 31, 2015) (AGN – $312.50 – NYSE) markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally. A combination with Pfizer is pending and should close sometime this year.





From the GAMCO Global Growth Fund fourth quarter 2015 commentary.



Check out Mario Gabelli latest stock trades

Baron Funds Comments on Allergan - Jan 27, 2016

Allergan plc (NYSE:AGN) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing brand, generic and biosimilar products. Probably best known for its Botox, Allergan has undergone a massive, M&A driven transformation after combinations with Forest Labs ($25 billion) and Actavis ($66 billion) have created a $120 billion behemoth. In the process, the company has upgraded its quality of earnings and diversified away from legacy dermatology and ophthalmology businesses. Our analysis suggested that Allergan’s earnings could rise from about $15/share this year, to about $25/share in five years making it attractive enough to initiate a small position. Late in the fourth quarter, Pfizer made a long speculated cash and stock bid to acquire Allergan at about a 20% premium to its price. So-called “tax inversion” is one of the goals analysts believe Pfizer was after in attempting to acquire Allergan, and various U.S. politicians have spoken out about the need to try and prevent these kinds of transactions. We believe Allergan should do well regardless of whether this deal will go through or not (although, we think that it will) as the stock did not move and continues to trade at about 20% discount to Pfizer’s offer price.



From the Baron Fifth Avenue Growth Fund Fourth Quarter 2015 Letter.



Check out Ron Baron latest stock trades

Weitz Funds Comments on Allergan - Jan 25, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Shares of Allergan were volatile during the quarter, providing us the opportunity to meaningfully increase our position at attractive prices. Following several months of speculation, Pfizer and Allergan announced their intention to combine on November 23rd. Assuming the deal is consummated as presently structured, Allergan shareholders would receive 11.3 shares of the combined Pfizer-Allergan for each existing Allergan share. Potential tax and regulatory hurdles remain, but we are optimistic on Allergan’s business prospects in either scenario - standalone or in combination with Pfizer. We have generally positive impressions from ongoing diligence on Pfizer’s business.



From the Weitz Funds' Research Fund shareholder letter for fourth quarter 2015.



Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Allergan - Jan 22, 2016

Allergan (NYSE:AGN) is a global specialty pharmaceutical company focusing on the development, manufacturing, marketing and distribution of generic, brand name, biosimilar and over-the-counter (OTC) pharmaceutical products. Shares of Allergan were volatile during the quarter, providing us the opportunity to meaningfully increase our position at attractive prices. Following several months of speculation, Pfizer and Allergan announced their intention to combine on November 23rd. Assuming the deal is consummated as presently structured, Allergan shareholders would receive 11.3 shares of the combined Pfizer-Allergan for each existing Allergan share. Potential tax and regulatory hurdles remain, but we are optimistic on Allergan’s business prospects in either scenario - standalone or in combination with Pfizer. We have generally positive impressions from ongoing diligence on Pfizer’s business.

From Wallace Weitz (Trades, Portfolio)'s fourth quarter 2015 Value Fund commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about Allergan PLC

John Paulson Reduces Synergy Pharmaceuticals After Heavy 3rd Quarter Health Care Selling Guru unloads another health care stock
John Paulson (Trades, Portfolio) axed another health care position on Nov. 30, he reported Tuesday, after backtracking on his huge exposure to the sector in the third quarter. Read more...
Allergan Receives FDA Clearance For the CoolSculpting® Treatment To Improve Appearance Of Lax Tissue In The Double Chin
Weekly CEO Buys Highlight Details the CEO buys this past week for the following companies: American Assets Trust, Aptiv PLC, TiVo, Allergan PLC and CenturyLink
According to GuruFocus Insider Data, these are the largest CEO buys during the past week.  Read more...
Weekly Top Insider Buys Highlight for the Week of Dec. 8 The largest Insider Buys this week were for Allergan PLC (AGN), Kinder Morgan Inc. (KMI), Annaly Capital Management Inc. (NLY), and Andeavor Logistics LP (ANDX).
The largest Insider Buys this week were for Allergan PLC (NYSE:AGN), Kinder Morgan Inc. (NYSE:KMI), Annaly Capital Management Inc. (NYSE:NLY), and Andeavor Logistics LP (NYSE:ANDX). Read more...
Why the Latest Data Is a Big Deal for Revance Therapeutics The company just became a potential buyout candidate in the biotech space
California-based Revance Therapeutics Inc. (NASDAQ:RVNC) is soaring on the back of the company releasing data from one of its lead development programs. At the midway point ­of the session in the U.S., the company is trading at a circa 40% premium to its preannouncement market capitalization at $36.30 a share with a market cap of $1.19 billion. Read more...
Building a Circle of Competency My journey of building a circle of competency in the pharmaceutical business
In my previous article I shared my favorite quotes from Li Lu on the subject of circle of competency. While those quotes are great, they won’t have any practical value unless we can actually put them into practice. Today I’ll share my journey of building a circle of competency (could very well be a circle of incompetence) in the pharmaceutical business. Read more...
Wallace Weitz Boosts DXC Technology, Allergan Holdings Weitz Investment's largest buys of the 3rd quarter
Weitz Investment Management founder Wallace Weitz (Trades, Portfolio) invested in the following stocks in the third quarter. Read more...
Allergan's Migraine Leadership Recognized with Enrico Greppi Award for Excellence in Headache Research
Research Report Identifies Allergan, Johnson & Johnson, Ford Motor, CSX, Gamestop, and L Brands with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Allergan to Present at the 2017 Citi Global Healthcare Conference

Ratios

vs
industry
vs
history
Forward PE Ratio 10.82
AGN's Forward PE Ratio is ranked higher than
78% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. AGN: 10.82 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 0.87
AGN's PB Ratio is ranked higher than
88% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. AGN: 0.87 )
Ranked among companies with meaningful PB Ratio only.
AGN' s PB Ratio Range Over the Past 10 Years
Min: 0.85  Med: 1.74 Max: 5.9
Current: 0.87
0.85
5.9
PS Ratio 3.77
AGN's PS Ratio is ranked lower than
65% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. AGN: 3.77 )
Ranked among companies with meaningful PS Ratio only.
AGN' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 1.95 Max: 13.79
Current: 3.77
0.99
13.79
Price-to-Free-Cash-Flow 20.52
AGN's Price-to-Free-Cash-Flow is ranked lower than
92% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. AGN: 20.52 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.73  Med: 19.19 Max: 324.48
Current: 20.52
6.73
324.48
Price-to-Operating-Cash-Flow 15.48
AGN's Price-to-Operating-Cash-Flow is ranked lower than
88% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. AGN: 15.48 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.06  Med: 15.14 Max: 96.59
Current: 15.48
6.06
96.59
EV-to-EBIT -8.73
AGN's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. AGN: -8.73 )
Ranked among companies with meaningful EV-to-EBIT only.
AGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -310.4  Med: 8.95 Max: 104.6
Current: -8.73
-310.4
104.6
EV-to-EBITDA -30.17
AGN's EV-to-EBITDA is ranked lower than
88% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. AGN: -30.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
AGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 12.5 Max: 589.4
Current: -30.17
-224.1
589.4
EV-to-Revenue 5.62
AGN's EV-to-Revenue is ranked lower than
72% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. AGN: 5.62 )
Ranked among companies with meaningful EV-to-Revenue only.
AGN' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 2.3 Max: 20.8
Current: 5.62
1.2
20.8
Shiller PE Ratio 73.09
AGN's Shiller PE Ratio is ranked lower than
68% of the 204 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.18 vs. AGN: 73.09 )
Ranked among companies with meaningful Shiller PE Ratio only.
AGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.96  Med: 56.82 Max: 2307.73
Current: 73.09
18.96
2307.73
Current Ratio 1.18
AGN's Current Ratio is ranked lower than
82% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. AGN: 1.18 )
Ranked among companies with meaningful Current Ratio only.
AGN' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.93 Max: 9.8
Current: 1.18
0.99
9.8
Quick Ratio 1.08
AGN's Quick Ratio is ranked lower than
73% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. AGN: 1.08 )
Ranked among companies with meaningful Quick Ratio only.
AGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 2.08 Max: 8.82
Current: 1.08
0.78
8.82
Days Inventory 147.07
AGN's Days Inventory is ranked lower than
65% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. AGN: 147.07 )
Ranked among companies with meaningful Days Inventory only.
AGN' s Days Inventory Range Over the Past 10 Years
Min: 108.11  Med: 126.6 Max: 369.82
Current: 147.07
108.11
369.82
Days Sales Outstanding 66.23
AGN's Days Sales Outstanding is ranked higher than
56% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. AGN: 66.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.05  Med: 65.51 Max: 197.04
Current: 66.23
39.05
197.04
Days Payable 50.30
AGN's Days Payable is ranked lower than
60% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. AGN: 50.30 )
Ranked among companies with meaningful Days Payable only.
AGN' s Days Payable Range Over the Past 10 Years
Min: 28.64  Med: 69.22 Max: 109.48
Current: 50.3
28.64
109.48

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.61
AGN's Dividend Yield % is ranked lower than
68% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. AGN: 1.61 )
Ranked among companies with meaningful Dividend Yield % only.
AGN' s Dividend Yield % Range Over the Past 10 Years
Min: 0.28  Med: 0.6 Max: 1.66
Current: 1.61
0.28
1.66
Forward Dividend Yield % 1.65
AGN's Forward Dividend Yield % is ranked lower than
57% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.05 vs. AGN: 1.65 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.66
AGN's 5-Year Yield-on-Cost % is ranked lower than
74% of the 849 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. AGN: 1.66 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AGN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.28  Med: 0.6 Max: 1.66
Current: 1.66
0.28
1.66
3-Year Average Share Buyback Ratio -24.30
AGN's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. AGN: -24.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -6.7 Max: 2
Current: -24.3
-45.6
2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.76
AGN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
84% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. AGN: 0.76 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.2 Max: 4.58
Current: 0.76
0.59
4.58
Price-to-Median-PS-Value 1.94
AGN's Price-to-Median-PS-Value is ranked lower than
90% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. AGN: 1.94 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 2.06 Max: 6.3
Current: 1.94
0.63
6.3
Earnings Yield (Greenblatt) % -11.45
AGN's Earnings Yield (Greenblatt) % is ranked lower than
78% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. AGN: -11.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.6  Med: 1.05 Max: 12.3
Current: -11.45
-11.6
12.3
Forward Rate of Return (Yacktman) % 9.20
AGN's Forward Rate of Return (Yacktman) % is ranked lower than
53% of the 397 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.07 vs. AGN: 9.20 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8  Med: 7 Max: 16.1
Current: 9.2
-8
16.1

More Statistics

Revenue (TTM) (Mil) $15,478.90
EPS (TTM) $ -21.56
Beta1.19
Short Percentage of Float2.99%
52-Week Range $160.76 - 256.80
Shares Outstanding (Mil)332.58

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 15,902 15,649 16,138 17,380
EPS ($) 16.26 15.74 16.85 19.40
EPS without NRI ($) 16.26 15.74 16.85 19.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.82%
Dividends per Share ($) 1.87 1.89 1.59 3.48

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}